Trial reportCell reports. Medicine2021
Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma.
Open access · goldAbstract readClinical Trial
In one paragraph
Trial report in Cell reports. Medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
3.3field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 54 citations in OpenAlex.
- CCL3+ Neutrophil Signature Predicts Response to Neoadjuvant Toripalimab plus Chemotherapy in Patients with Hypopharyngeal Squamous Cell Carcinoma: A Phase II Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Optimizing immunotherapy for head and neck squamous cell carcinoma: recent advances and future directions.Annals of medicine · 2026Review
- TCASIA: an integrative atlas linking alternative splicing landscapes for cancer immunotherapy.Journal for immunotherapy of cancer · 2026Article
- ZC3H13-mediated m6A stabilization of CCND1 promotes malignant progression and is associated with poor anti-PD-1 response in HNSCC.Clinical and translational medicine · 2026Article
- Loss of JAK1 Function Causes G2-M Cell-Cycle Defects Vulnerable to KIF18A Inhibition.Cancer research · 2026Article
- Advances in endometrial cancer screening: a comprehensive review of current methods and emerging technologies.International journal of clinical oncology · 2026Review
- Migrasomes constrained by a homologous-targeting photodynamic nanoplatform: enhancing intratumoral CD8Journal of nanobiotechnology · 2026Article
- The emerging role of neoadjuvant immunotherapy in locally advanced oral squamous cell carcinoma: progress and challenges.International journal of surgery (London, England) · 2026Article
- Tumor lactate metabolism shapes immune suppression and therapeutic resistance revealed by integrative multi-omics and digital pathology.Frontiers in immunology · 2026Article
- Article
- Integrating clinicopathologic factors with whole-exome sequencing and peripheral immune repertoire sequencing to optimize decision-making in neoadjuvant chemoimmunotherapy for HNSCC.Frontiers in immunology · 2026Article
- Interferon Epsilon Loss Is Elusive 9p21 Link to Immune-Cold Tumors, Resistant to Immune Checkpoint Therapy, and Endogenous CXCL9/10 Induction.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025Review
- Longitudinal liquid biopsy identifies an early predictive biomarker of immune checkpoint blockade response in head and neck squamous cell carcinoma.Nature communications · 2025Article
- CDKN2A deletion is associated with immune desertification in diffuse pleural mesothelioma.Journal of experimental & clinical cancer research : CR · 2025Article
- Exploring the role of PANoptosis related genes in the prognosis of oral squamous cell carcinoma subtypes based on multi-omics analysis.Discover oncology · 2025Article
- Blockade of the PGE2 Pathway Inhibits the Growth of PTEN-Deficient HNSCC Tumors.Molecular cancer therapeutics · 2025Article
- Immunohistochemistry for Skin Cancers: A Comprehensive Approach to the Diagnosis of Squamous Cell Carcinoma.Cancers · 2025Review
- Induced B cell receptor diversity predicts PD-1 blockade immunotherapy response.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Anti-EGFR enhanced neoadjuvant immunotherapy versus neoadjuvant immunochemotherapy for locally advanced oral squamous cell carcinoma.Frontiers in immunology · 2025Article
- Metal-dependent cell death resistance contribute to lymph node metastasis of oral squamous cell carcinoma.Frontiers in cell and developmental biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 4 institutions in 1 country.
Sixue LiuDivision of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Hannah M KnochelmannDepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC 29425, USA.
Shirley H LomeliDivision of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Aayoung HongDivision of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Mary RichardsonDepartment of Pathology, Medical University of South Carolina, Charleston, SC 29425, USA.
Zhentao YangDivision of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Raymond J LimDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Yan WangDivision of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Camelia DumitrasDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Kostyantyn KrysanDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Cynthia TimmersIncyte Pharmaceuticals, Wilmington, DE 19803, USA.
Martin J RomeoHollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA.
Carsten KriegDepartment of Immunology and Microbiology, Medical University of South Carolina, Charleston, SC 29425, USA.
Elizabeth C O'QuinnHollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA.
Joshua D HortonDepartment of Otolaryngology - Head and Neck Surgery, Medical University of South Carolina, Charleston, SC 29425, USA.
Steve M DubinettDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Chrystal M PaulosDivision of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA.
David M NeskeyHollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA.
Roger S LoDivision of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
University of California, Los Angeles · USMedical University of South Carolina · USEmory University · USIncyte (United States) · US
Funding
Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5MTranslational Science Laboratory Shared ResourceP30CA138313 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI Jian Ouyang · 2009 to 2026
$42.7MSouth Carolina Clinical & Translational Research Institute (SCTR)UL1TR001450 · NCATS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BRADY, KATHLEEN T., FLUME, PATRICK A · 2015 to 2024
$41.1MProject 3: Modeling and overcoming resistance to melanoma immunotherapyP01CA244118 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MORICEAU, GATIEN P · 2020 to 2024
$12.8MUCLA Tumor Immunology Training ProgramT32CA009120 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Steven M. Dubinett, MICHAEL A TEITELL · 1985 to 2026
$10.3MTARGETED COMBINATORIAL TREATMENT OF BRAF MELANOMASP01CA168585 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DRY, SARAH M. · 2013 to 2017
$8.4MPreventing MAPK inhibitor resistance in melanoma by targeting genomic instability and immune resistanceR01CA176111 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ROGER S LO · 2013 to 2026
$5.4MMechanisms of durable antitumor immunity via CD26hiCD4+ T cellsR01CA208514 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI PAULOS, CHRYSTAL MARY · 2016 to 2020
$1.7MCostimulatory mechanisms of antitumor Th17 cell immunityR01CA175061 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI PAULOS, CHRYSTAL MARY · 2013 to 2017
$1.5MDefining the Role of CD26 in Checkpoint Blockaded Induced Tumor ImmunityR21DE029592 · NIDCR · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI NESKEY, DAVID M., PAULOS, CHRYSTAL MARY · 2020 to 2021
$411kThe tumor suppressor capability of p53 is dependent on Non-muscle Myosin IIA function in Head and Neck Cancer.K08DE026542 · NIDCR · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI NESKEY, DAVID M. · 2016 to 2018
$405kUnderstanding PD-L1/L2 protein regulation, detection and signaling to predict melanoma therapeutic sensitivityR21CA255837 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LO, ROGER S · 2021 to 2022
$397kNCATS NIH HHS UL1 TR001450NCI NIH HHS P01 CA168585NCI NIH HHS P01 CA244118NCI NIH HHS P30 CA016042NCI NIH HHS P30 CA138313NCI NIH HHS R01 CA175061NCI NIH HHS R01 CA176111NCI NIH HHS R01 CA208514NCI NIH HHS R21 CA215910NCI NIH HHS R21 CA255837NCI NIH HHS T32 CA009120NIDCR NIH HHS K08 DE026542NIDCR NIH HHS R21 DE029592
Abstract
Neoadjuvant PD-1 blockade may be efficacious in some individuals with high-risk, resectable oral cavity head and neck cancer. To explore correlates of response patterns to neoadjuvant nivolumab treatment and post-surgical recurrences, we analyzed longitudinal tumor and blood samples in a cohort of 12 individuals displaying 33% responsiveness. Pretreatment tumor-based detection of
Indexed as
Antineoplastic Agents, ImmunologicalCarcinoma, Squamous CellCyclin-Dependent Kinase Inhibitor p16Gene Expression ProfilingGene Expression Regulation, NeoplasticHumansImmune Checkpoint InhibitorsJanus Kinase 2Mouth NeoplasmsMutationNeoadjuvant TherapyNeoplasm Recurrence, LocalNivolumabProgrammed Cell Death 1 ReceptorPTEN PhosphohydrolaseReceptors, Antigen, T-Cell, alpha-betaAntineoplastic Agents, ImmunologicalCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16FLT4 protein, humanImmune Checkpoint InhibitorsJAK2 protein, humanJanus Kinase 2NivolumabPDCD1 protein, humanProgrammed Cell Death 1 ReceptorPTEN PhosphohydrolasePTEN protein, humanReceptors, Antigen, T-Cell, alpha-betaVascular Endothelial Growth Factor Receptor-3YAP1 protein, humanYAP-Signaling ProteinsFLT4/PTEN/PPARG/CDKN2A/YAP1/JAK2head-and-neck cancer/oral-cavity SCCmultiplex immunofluorescenceneoadjuvant anti-PD-1/L1 therapyrecurrence-free survivalresponse, resistance, and recurrenceT cell repertoireT regulatory to Th17 ratiotumor mutational burdentumor phylogeny
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.